Latest News

Improved guidance on preservatives and allergens needed to ensure safety.

Real-world data shows systemic immunomodulators beat local steroids for chronic uveitis, cutting glaucoma, cataract, CME, and ERM risks.

Bonnie An Henderson, MD, founder of EnVision Summit, highlights how the annual conference integrates MD and OD tracks, practical subspecialty updates, and structured opportunities for connection across career stages.

Large study links specific retinal findings to leukemia subtype, predicting remission risk and visual prognosis—prompt eye exams can flag relapse early.

Trial shows AAV8 PDE6A gene therapy doesn’t improve retinitis pigmentosa vision in a year and may cause retinal thinning and VA loss.

Most patients do well on topical therapy, but innovation in IOP-lowering drops remains essential.

ACP says the label “provider” blurs clinical roles, commercializes care, and erodes trust—urging words that protect medical ethics and relationships.

New AAV therapy for retinitis pigmentosa completes Phase I/II dosing, aiming to protect cones and slow vision loss; first readout targets 2027.

Aaron Y. Lee, MD, MSCI, explains how temporal optical coherence tomography modeling may improve longitudinal disease tracking and clinical decision-making.

The primary endpoint of the trial is non-inferiority in the mean change from baseline in best-corrected visual acuity (BCVA) at 52 weeks.

The results of a multicenter controlled clinical trial showed that the device resulted in “a significant improvement in visual acuity (VA) from baseline to month 12.

P. Dee G. Stephenson, MD, FACS, shares insights on evolving LAL technology and best practices for managing the ocular surface before and after surgery.